Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > REGULATORY
REGULATORY
- MHLW to Study Overseas Generic Drug Markets to Support Globalization of Domestic Industry
September 10, 2012
- “Some Problems” Found with UMN Pharma’s Cell Culture Method Development Project: MHLW
September 7, 2012
- Labor Standards Bureau Head Junichi Kaneko to Be Appointed Vice Minister of Health; Pension Bureau Head Jun Ebata to Be Transferred to PFSB: MHLW
September 6, 2012
- MHLW to Request 41.1 Bil. Yen in FY2013 Budget for Drug Discovery Support and Other Special Priority Projects
September 6, 2012
- Project to Develop Vaccines for New Influenza Strains Using Chicken Egg Culture Method Receives “A” Grade: MHLW
September 4, 2012
- 3 Generics with 2 APIs Found to Be Non-Compliant in FY2011 Quality Assurance Project: MHLW
September 4, 2012
- PAFSC’s 1st Committee Recommends Approval for Bayer Yakuhin’s AMD Drug
September 3, 2012
- JPWA, NPhA Confirm Further Efforts Needed to Increase Awareness among Members Amid Lag in Distribution Improvements
September 3, 2012
- MHLW to Seek Funds to Enhance Regulatory Consultation under FY2013 “Priority Budget Scheme”
September 3, 2012
- 1,220 Reports of Adverse Events Associated with OTC Drugs Including 24 Deaths Reported in 5 Years: MHLW
August 31, 2012
- DPJ Submits Bill to Form Third-Party Monitoring Organization for Pharmaceutical Affairs
August 30, 2012
- MHLW to Include Creation of Drug Discovery Support Network in FY2013 Draft Budget Request
August 30, 2012
- MHLW Adds Six APIs/10 Products Including Tenelia to NHI Price List
August 29, 2012
- PMDA Eyes World’s First Approval for New Drugs: Chief Executive Kondo
August 28, 2012
- Drug-Dispensing Expenditure Rises 7.9% to 6,513.3 Billion Yen in FY2011: MHLW
August 28, 2012
- PAFSC 2nd Committee to Review 5 Products Including Novartis’s COPD Drug on Sept. 6
August 24, 2012
- Domestic Pharmaceutical Production Up 3.1 %, to Record high 6,987.4 Bil. Yen in 2011
August 24, 2012
- Two Healthcare Provider Reps at CSIMC Criticize Marketing of a Single Drug under Different Brand Names as “Undesirable”
August 24, 2012
- CSIMC Expert Subcommittee Favors Single Index for Efficacy Assessment of Medical Technology
August 24, 2012
- Drug Pricing Subcommittee Presents Negative Views on Reference Pricing System; “Concerns over Patient Copayment Increases”
August 24, 2012
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…